Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · Real-Time Price · USD
23.77
+0.38 (1.60%)
At close: Feb 21, 2025, 4:00 PM
23.81
+0.04 (0.19%)
After-hours: Feb 21, 2025, 7:03 PM EST
Structure Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Structure Therapeutics stock have an average target of 81.29, with a low estimate of 50 and a high estimate of 118. The average target predicts an increase of 242.06% from the current stock price of 23.77.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 8, 2025.
Analyst Ratings
The average analyst rating for Structure Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 6 | 6 | 6 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +110.39% | Jan 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +236.63% | Dec 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +236.63% | Dec 19, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $91 | Buy | Reiterates | $91 | +282.92% | Dec 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +236.63% | Dec 4, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
46.36M
EPS This Year
-0.82
from -2.44
EPS Next Year
-0.82
from -0.82
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 525.0M | n/a | |||
| Avg | n/a | 46.4M | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.77 | 2.04 | -0.99 | |||
| Avg | -0.82 | -0.82 | -1.35 | |||
| Low | -1.00 | -1.54 | -1.61 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.